Clinical Trials
584 trialsPOM MM 014
Celgene
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Medical College of Wisconsin
COSMIC
ASH Research Collaborative
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
Otsuka Pharmaceutical Development & Commercialization, Inc.
KEYNOTE145
Acerta Pharma BV
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Mayo Clinic
DREAMM 14
GlaxoSmithKline
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Flu-Mel-Vel
Hackensack Meridian Health
RZD
Hackensack Meridian Health
Thal/Mel/Vel
Hackensack Meridian Health
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
Thomas Jefferson University
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Janssen Research & Development, LLC
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Wake Forest University Health Sciences
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
MagnetisMM-9
Pfizer
IKEMA
Sanofi
Imaging in MGUS, SMM and MM
National Institutes of Health Clinical Center (CC)
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Medical College of Wisconsin
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
University of Chicago
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Fred Hutchinson Cancer Center
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
EMN14
European Myeloma Network B.V.
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Thomas Jefferson University
Health Through Activity: A Pilot Study of a Rehabilitation Intervention for People Living With Multiple Myeloma
MGH Institute of Health Professions
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Acerta Pharma BV
Home Based Daratumumab Administration for Patients With Multiple Myeloma
Thomas Jefferson University
High Dose Carfilzomib for Newly Diagnosed Myeloma
Memorial Sloan Kettering Cancer Center
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma
Cedars-Sinai Medical Center
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
A Study of Colesevelam for Lenalidomide-Associated Diarrhea
Memorial Sloan Kettering Cancer Center
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
Brown University
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
ASCENT
Mayo Clinic
(Mel/MelVel)
Hackensack Meridian Health
Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy
Emory University
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Mayo Clinic
SELECT
Amgen